Autors:

CiteWeb id: 20100000149

CiteWeb score: 2464

DOI: 10.1016/S1470-2045(09)70364-X

Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor ( EGFR ) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.

The publication "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial" is placed in the Top 10000 of the best publications in CiteWeb. Also in the category Other it is included to the Top 1000. Additionally, the publicaiton "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial" is placed in the Top 1000 among other scientific works published in 2010.
Links to full text of the publication: